Affymetrix and Medical Prognosis Institute Collaborate to Develop Cancer Treatment Products

Affymetrix Inc. (Nasdaq:AFFX) and Medical Prognosis Institute A/S (MPI), a leading cancer diagnostic development company based in Denmark, today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. With this agreement, MPI gains non-exclusive access to Affymetrix microarray technology to develop and commercialize drug sensitivity prediction and prognostic products for patients with cancer.

Source: Affymetrix